Balance Sheet Information (Tables)

9 Months Ended

Sep. 30, 2023

Balance Sheet Related Disclosures [Abstract]

Schedule of cash and cash equivalents and restricted cash

A summary of cash and cash equivalents and restricted cash is as follows:

	September 30, 2023		December 31, 2022
Cash and Cash Equivalents	$	5,400,498	$	5,964,556
Restricted Cash, Non-current	4,031		49,260
Total Cash, Cash Equivalents and Restricted Cash	$	5,404,529	$	6,013,816

Schedule of restricted cash

A summary of cash and cash equivalents and restricted cash is as follows:

	September 30, 2023		December 31, 2022
Cash and Cash Equivalents	$	5,400,498	$	5,964,556
Restricted Cash, Non-current	4,031		49,260
Total Cash, Cash Equivalents and Restricted Cash	$	5,404,529	$	6,013,816

Schedule of prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following:

	September 30, 2023		December 31, 2022
Prepaid Insurance	$	116,853	$	117,315
Prepaid Research and Development	49,377		128,429
Other	73,161		97,325
Total Prepaid Expenses and Other Current Assets	$	239,391	$	343,069

Schedule of accrued expenses

Accrued expenses consist of the following:

	September 30, 2023		December 31, 2022
Payroll and Benefits	$	828,694	$	1,312,443
Professional Fees	68,819		282,721
Clinical Trials	424,026		57,020
Other	140,172		183,750
Total Accrued Expenses	$	1,461,711	$	1,835,934